Matthias Brand
Chief Technology Officer & Co-founder Proxygen GmbH
Seminars
Thursday 30th October 2025
Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
11:00 am
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
Thursday 30th October 2025
Novel Molecular Glue Degraders of P300 & Mechanistic Characterization of Determinants of Selectivity Over Closely Related Paralog CBP
9:45 am
- Monovalent molecular glue degraders for histone acetyltransferase P300 (P300), a high-profile epigenetic target, were identified using Proxygen’s ligaseagnostic screening platform
- Molecular glue induces endogenous p300 degradation and modulates downstream signaling pathways recapitulating genetic dependencies in selected indications
- Ternary complex structural elucidation (Cryo-EM), Molecular Dynamics modeling, combined with biochemical and cellular characterization enabled rational drug design and optimization of preferential degradation of P300 over CREB-binding protein (CBP)
